Best of the Week
Most Popular
1.Scottish Independence YES Vote Panic - Scotland Committing Suicide and Terminating the UK? - Nadeem_Walayat
2.Independent Scotland Will Disintegrate as Unionist Regions Demand Referendum's to Rejoin UK - Nadeem_Walayat
3.Bank of England Panic! Scottish Independence Bank Run Already Underway! - Nadeem_Walayat
4.Gold and Silver Price Ready To Go BOOM - Austin_Galt
5.Gold and Silver Potential Price Meltdown Scenario - Rambus_Chartology
6.Scottish Independence UK Catastrophe - The Balkanisation of Britain - Video - Nadeem_Walayat
7.The Price Of Gold And The Art Of War Part I - Darryl_R_Schoon
8.Main Reason Why Scotland Will Vote NO to Independence, 70% Probability - Nadeem_Walayat
9.Heavy Gold and Silver Shorting is Bullish - Zeal_LLC
10.10 Year U.S. Treasury Short Best Place to be Remainder of 2014 - EconMatters
Last 5 days
Is Citigroup the Dumbest Bank Ever? - 18th Sept 14
Scotland Must Vote Yes! For All Of Us - 18th Sept 14
Scottish Independence Referendum Result NO 55%, YES 45% - Vote Forecast - 18th Sept 14
A Public Bank Option for and Independent Scotland - 17th Sept 14
The Charade of Independence for Scotland and UKIP - 17th Sept 14
Gold Report - U.S. National Debt Surges $1 Trillion In Just 12 Months - 17th Sept 14
How to Find Trading Opportunities in ANY Market Using Fibonacci Analysis - 17th Sept 14
Why Money Is Worse Than Debt - 17th Sept 14
Can Gold Price Finally Recover? - 17th Sept 14
Scotland Independence - Europe Holds Its Breath - 17th Sept 14
The Energy Prices at Risk with Scottish Independence - 17th Sept 14
Scottish Independence SNP Lies on NHS, Economy, Debt, Oil and Currency - 17th Sept 14
The Truth Behind the Dangerous "Helicopter Money" Delusion - 16th Sept 14
Central Bank Balance Bullying: Investor Implications - 16th Sept 14
U.S. Dollar and Gold Elliott Wave Projection - 16th Sept 14
The Origins and Implications of the Scottish Referendum - 16th Sept 14
The Collapse Of U.S. Silver Stocks As Public Debt Skyrockets - 16th Sept 14
Emerging Markets Are Set Up for a Crisis, What’s on Your Radar Screen? - 16th Sept 14
Scottish Independence Bank Run Already Underway - Video - 16th Sept 14
The Emergence of the US Petro-Dollar - 16th Sept 14
Economic GDP Drives Stock Prices Inestment Myth - 16th Sept 14
Don't Miss This Gold Buying Opportunity - 16th Sept 14
Why ECB QE Is Bearish For Gold Prices - 15th Sept 14
Property Rights and Property Taxes—and Countries That Don’t Have Them - 15th Sept 14
Junior Miners Breaking Out Higher Forecasting Gold and Silver Price Bottom? - 15th Sept 14
Stock Market Patiently Waiting for Mean Reversion - 15th Sept 14
A Closer Look at the US Dollar - 15th Sept 14
The Silver Price Sentiment Cycle - 15th Sept 14
Stock Market Correction Underway - 15th Sept 14
Marc Faber - “I Want To Be Diversified, I Want To Own Some Gold” - 15th Sept 14
The Myth of Nuclear Weapons - 15th Sept 14
US Dollar Forecast to Go Much Higher - 15th Sept 14
Analysis And Price Projection Of The Uranium Market - 15th Sept 14
Bank of England Panic! Scottish Independence Bank Run Already Underway! - 15th Sept 14
The Ethics of Entrepreneurship and Profit - 14th Sept 14
The Big Investor Opportunity in the Orbital Space Junkyard - 14th Sept 14
Kohl's and The Rest of The Retailers are in Deep Doo Doo - 14th Sept 14
Independent Scotland Will Disintegrate as Unionist Regions Demand Referendum's to Rejoin UK - 14th Sept 14
Stock Market Pullback Continues - 13th Sept 14
SNP Fanatics Warn of Day of Reckoning for Scottish Independence No Campaigners - 13th Sept 14
Scottish Independence Would Shake Up the Global System - 13th Sept 14
The World Order Becomes Disorder - 13th Sept 14
Is Geothermal Power About to Become The Next Great Battleground Over Fracking? - 12th Sept 14
Heavy Gold and Silver Shorting is Bullish - 12th Sept 14
Strong U.S. Dollar Undermines Gold and Silver - 12th Sept 14
Debt And The Decline Of Money - 12th Sept 14
Panic On The Streets Of London ... Can Scotland Ever Be The Same Again? - 12th Sept 14
Will The Real Silver Commercials Stand Up? - 12th Sept 14
If You Own Only One Investment, Make Sure This Is It - 12th Sept 14
Main Reason Why Scotland Will Vote NO to Independence, 70% Probability - 12th Sept 14
Better Days Ahead For U.S. Stock And Housing Market - 12th Sept 14
U.S. Meddling Dims Prospects for Ukraine Peace - 12th Sept 14
Is the Fed Preparing to Asset-Strip Local Governments? - 12th Sept 14

Free Instant Analysis

Free Instant Technical Analysis


Market Oracle FREE Newsletter

Huge Stocks Bear Market

The Next Profit Breakthrough: Synthetic Biology

Companies / BioTech Dec 13, 2012 - 06:17 AM GMT

By: Money_Morning

Companies

Michael A. Robinson writes: Drug, chemical, and biofuel firms are relying more than ever on artificial fragments of DNA to invent new products. It's called synthetic biology.

For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.


Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.

Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.

Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.

Now, Gen9 is a small, new dynamic company. And its potential is huge.

It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.

Even better, it cuts the cost of that process by leaps and bounds.

A Huge Breakthrough in Synthetic Biology
The system this company created is known as BioFab. This system can quickly and cheaply produce tens of thousands of double-stranded DNA fragments. Talk about economies of scale -- it's this bulk processing that gives Gen9 such a huge advantage over other firms.

It works like this: BioFab can produce tens of thousands of double-stranded DNA fragments that are between 500 and 1,000 base pairs in length. Gen9 says it can produce the synthetic DNA for less than 10 cents per base pair, which the company says is as little as 20% the cost of other firms.

No wonder the small company is attracting so much buzz from scientists and professional investors.

The world is moving at warp speed, and it is firms like Gen9 that are pushing the pace of scientific and medical breakthroughs. Of course, this field will play a big role in the future of the human race.

And more to the point, there also will be a payoff for us investors as well. That's why I think Gen9 needs to be on your radar screen. I predict this company will go public in the next few years. Failing that, I believe it will license its technology to other publicly traded firms.

In the meantime, I expect both biotech and drug firms to work with Gen9. Doing so will increase profit margins for those firms and their investors.

Gen9 is Poised to Make Investors Serious Money
Of course, great tech alone is no guarantee of success. But Gen9 has three bases covered that are critical for making money in this sector:

•It's a leader in a breakthrough field that is part of a major trend with strong global demand that will continue for at least two decades.
•Gen9 is attracting high-profile professional investors who know what steps a startup must take to have a profitable IPO and to succeed in the long run.
•The company has great management.

We've covered much of the first item already. But let me add this -- the field has grown by leaps and bounds just since 2010. That's when a team at the J. Craig Venter Institute created the first living cell controlled completely by synthetic DNA.

Teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They also are growing new microorganisms that yield biofuels to be used in lieu of oil.

Second, Gen9 has not disclosed its total venture funding, but it has received money from Draper Fisher Jurvetson (DFJ), which has a great track record. DFJ has backed dozens of tech stars like Skype, athenahealth Inc. (Nasdaq:ATHN), Baidu Inc. (Nasdaq:BIDU) and Tesla Motors Inc. (Nasdaq:TSLA).

And for the third item on the success list, two of its top leaders have deep experience at publicly traded firms. CEO Kevin Munnelly joined Gen9 last July from Life Technologies Corp. (Nasdaq:LIFE) and COO Martin Goldberg spent 17 years with small-cap biotech leader Affymetrix Inc. (Nasdaq:AFFX).

The cofounders are no slouches, either. Check out their credentials:

•Joseph Jacobson is an associate professor at MIT. He has won several major awards and authored 70 peer-reviewed articles for scientific journals.
•George Church is a professor at Harvard Medical School. He has a long track record of commercializing human genomes.
•Drew Endy is a noted associate professor of bioengineering at Stanford University.

Let me close by noting that Gen9 also shows why the U.S. remains at the forefront of cutting-edge technology. As I often tell investors, the U.S. has so many bright minds working in cutting-edge fields that we just can't help but succeed in the long run.

And Gen9 promises to be one of the firms leading the way.

Source :http://moneymorning.com/2012/12/13/the-next-profit-breakthrough-synthetic-biology/

Money Morning/The Money Map Report

©2012 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2014 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Free Report - Financial Markets 2014